A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

Trial Profile

A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Diffuse scleroderma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2018.
    • 13 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
    • 13 Oct 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top